Skip to content
Research Article Open access CC BY 4.0

Biochemistry of Corona Virus: An Overveiw

Nwaogwugwu Joel Caleb, Victor Chukwubuike Nwankwo, Nweke Celestine Chimaobi, Ugoaghalam Uche James, Uchenna Samuel Igwe, Aguwamba Chinedu, Faith Nwokoma

Asian Journal of Biochemistry, Genetics and Molecular Biology · pp. 75–96 · Published 31 Oct 2022

10.9734/ajbgmb/2022/v12i4272

Abstract

Coronaviruses forma large family of respiratory viruses having positive (+ve)-stranded RNA (C0V).  Their names are derived from the crown-like shape that is present on their them (surface). The new viral strain SARS-CoV-2 was first discovered in Wuhan, China, in December 2019. Even though this virus can spread via airborne, direct, and indirect contact, the most typical way of infection transmission is through droplets. Like the other coronaviruses in the same family, it can causeeverything from minor flu-like symptoms like; cold, sore throat, cough, and fever, to very seriousones like; pneumonia and breathing difficulties. It also has the potential to be fatal. The primary constituents make up the coronavirus. For instance, the positive-stranded RNA molecule that the host cell will translate is carried by the endoplasm, cell membrane, and outer globular protein. The transit of substances into and out of the cell is regulated by the cell membrane and membrane protein. One or more of them include the pointed glycoprotein, envelope small membrane protein, hemagglutinin esterase, nucleoprotein, and genomic RNA. The second coronavirus that causes severe acute respiratory syndrome is the reason for the ongoing coronavirus disease epidemic known as covid-19 pandemic or coronavirus pandemic (SARS-COV-2). It was originally discovered in December 2019 in Wuhan, China. The World Health Organization (WHO) classified the outbreak as a pandemic and a public health emergency of global concern in January 2020 and March 2020, respectively. As of March 7th, 2021, COVID-19, one of the deadliest pandemics in recorded history, had been linked to over 2.59 million fatalities and over 11.7 million confirmed cases. Being vaccination is one of the steps you may take to protect yourself and others from getting infected with COVID-19. Protection from COVID-19 is essential since it can cause severe illness or death in some persons. It takes all the tools at our disposal to stop a pandemic. You can reduce your risk of getting sick or spreading the disease to others by taking additional precautions like wearing masks and avoiding social situations. Combining the COVID-19 vaccine with following the CDC’s recommendations for safeguarding both you and others will provide the best defense against the virus.

COVID-19 SARS-CoV-1 vaccine Hemagglutin esterase

References (36)

  1. 1 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  2. 2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
  3. 3 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
  4. 4 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 [DOI]
  5. 5 How will country-based mitigation measures influence the course of the COVID-19 epidemic? [DOI]
  6. 6 [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. [DOI]
  7. 7 The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 [DOI]
  8. 8 Effective treatment of severe COVID-19 patients with tocilizumab [DOI]
  9. 9 The spike protein of SARS-CoV — a target for vaccine and therapeutic development [DOI]
  10. 10 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys [DOI]
  11. 11 SARS-CoV-2 Vaccines: Status Report [DOI]
  12. 12 MERS, SARS and other coronaviruses as causes of pneumonia [DOI]
  13. 13 COVID-19: Transmission, prevention, and potential therapeutic opportunities [DOI]
  14. 14 TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes [DOI]
  15. 15 The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus [DOI]
  16. 16 Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination [DOI]
  17. 17 Coronavirus membrane fusion mechanism offers a potential target for antiviral development [DOI]
  18. 18 Recognition of aerosol transmission of infectious agents: a commentary [DOI]
  19. 19 Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors [DOI]
  20. 20 Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic [DOI]
  21. 21 The race for coronavirus vaccines: a graphical guide [DOI]
  22. 22 Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? [DOI]
  23. 23 Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies [DOI]
  24. 24 Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll‐like receptors [DOI]
  25. 25 Respiratory Performance Offered by N95 Respirators and Surgical Masks: Human Subject Evaluation with NaCl Aerosol Representing Bacterial and Viral Particle Size Range [DOI]
  26. 26 Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention [DOI]
  27. 27 Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) [DOI]
  28. 28 Antigen kinetics determines immune reactivity [DOI]
  29. 29 Understanding Human Coronavirus HCoV-NL63~!2009-11-13~!2010-04-09~!2010-05-25~! [DOI]
  30. 30 Cross-presentation of exogenous antigens on MHC I molecules [DOI]
  31. 31 A Review of Isolation Gowns in Healthcare: Fabric and Gown Properties [DOI]
  32. 32 Healthcare-Associated Atypical Pneumonia [DOI]
  33. 33 Cell replacement therapies to promote remyelination in a viral model of demyelination [DOI]
  34. 34 The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China [DOI]
  35. 35 [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. [DOI]
  36. 36 Genomic variance of the 2019-nCoV coronavirus [DOI]

Cited by 1

Recent developments in the therapeutics of SARS-CoV-2 infection

Priyanka Nagu, Arun Parashar, Pankaj Sharma · One Health Bulletin · 2024

Related research

Article metrics

Real usage data collected on this platform.

47

Page views

0

PDF downloads

8

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.